The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents

European Journal of Pharmacology

Volumn 671, Issue 1-3, 2011, Pages 39-44

  Dutta, Aloke K ^a   Gopishetty, Bhaskar ^a   Gogoi, Sanjib ^a   Ali, Solav ^b   Zhen, Juan ^b   Reith, Maarten ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Antidepressant; Dopamine; Monoamine transporter; Norepinephrine; Serotonin; Triple uptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; D 142; DOPAMINE TRANSPORTER; FLUOXETINE; IMIPRAMINE; NORADRENALIN TRANSPORTER; PYRAN DERIVATIVE; SEROTONIN TRANSPORTER; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SPECIFICITY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTOR ACTIVITY TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BIOLOGICAL TRANSPORT; CENTRAL NERVOUS SYSTEM; DRUG DISCOVERY; HINDLIMB SUSPENSION; MALE; MICE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; PYRANS; RATS; SWIMMING; SYMPORTERS;

EID: 80455176891     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.09.162     Document Type: Article

References (38)

1. J.A. Ascher, J.O. Cole, J.N. Colin, J.P. Feighner, R.M. Ferris, H.C. Fibiger, R.N. Golden, P. Martin, W.Z. Potter, and E. Richelson Bupropion: a review of its mechanism of antidepressant activity J. Clin. Psychiatry 56 1995 395 401
2. R.H. Baldessarini Goodman and Gilman's The Pharmacological Basis of the Therapeutica 1996 McGrawe Hills New York
3. R.J. Baldessarini L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's The Pharmnacological Basis of Therapeutics 11th ed 2006 McGraw-Hill New York 443
4. J.T. Barbey, and S.P. Roose SSRI safety in overdose J. Clin. Psychiatry 59 Suppl. 15 1998 42 48 (Pubitemid 28467477)
5. F.I. Carroll, P. Kotian, A. Dehghani, J.L. Gray, M.A. Kuzemko, K.A. Parham, P. Abraham, A.H. Lewin, J.W. Boja, and M.J. Kuhar Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter J. Med. Chem. 38 1995 379 388
6. M.H. Corrigan, A.Q. Denahan, C.E. Wright, R.J. Ragual, and D.L. Evans Comparison of pramipexole, fluoxetine, and placebo in patients with major depression Depress Anxiety 11 2000 58 65 (Pubitemid 30228411)
7. P.S. D'Aquila, M. Collu, G.L. Gessa, and G. Serra The role of dopamine in the mechanism of action of antidepressant drugs Eur. J. Pharmacol. 405 2000 365 373
8. B.W. Dunlop, and C.B. Nemeroff The role of dopamine in the pathophysiology of depression Arch. Gen. Psychiatry 64 2007 327 337 (Pubitemid 46376789)
9. A.K. Dutta, B. Ghosh, S. Biswas, and M.E. Reith D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action Eur. J. Pharmacol. 589 2008 73 79
10. J.D. Elsworth, J.R. Taylor, P. Berger, and R.H. Roth Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum Neurochem. Int. 23 1993 61 69
11. B.J. Goldstein, and P.J. Goodnick Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics J. Psychopharmacol. 12 1998 S55 87 Oxford, England)
12. M.B. Hamner, and B.I. Diamond Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study Psychiatry Res. 64 1996 209 211 (Pubitemid 26380240)
13. C. Hiemke, and S. Hartter Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol. Ther. 85 2000 11 28
14. D.C. Jimerson Role of dopamine mechanisms in affective disorder Psychopharmacology The third Generation of Progress 1987 Raven Press New York 505 511
15. P.S. Kharkar, A.M. Batman, J. Zhen, P.M. Beardsley, M.E. Reith, and A.K. Dutta Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy) ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperid in-3-ol and its stereoisomers for activity toward monoamine transporters Chem. Med. Chem. 4 2009 1075 1085
16. V. Klimek, J.E. Schenck, H. Han, C.A. Stockmeier, and G.A. Ordway Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study Biol. Psychiatry 52 2002 740 748
17. Y. Liang, and E. Richelson Triple reuptake inhibitors: next-generation antidepressants Prim. Psychiatry 2008 50 56 (Pubitemid 351556546)
18. Y. Liang, A.M. Shaw, M. Boules, S. Briody, J. Robinson, A. Oliveros, E. Blazar, K. Williams, Y. Zhang, P.R. Carlier, and E. Richelson Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) J. Pharmacol. Exp. Ther. 327 2008 573 583
19. M.J. Millan Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 2009 53 77
20. D. Mischoulon, A.A. Nierenberg, L. Kizilbash, J.F. Rosenbaum, and M. Fava Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians Can. J. Psychiatry 45 2000 476 481
21. M.J. Owens, and C.B. Nemeroff The serotonin transporter and depression Depress Anxiety 8 Suppl. 1 1998 5 12 (Pubitemid 28524840)
22. R.D. Porsolt, M. Le Pichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatments Nature 266 1977 730 732 (Pubitemid 8073804)
23. E. Richelson Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance J. Clin. Psychiatry 64 Suppl. 13 2003 5 12 (Pubitemid 37267809)
24. A. Roy, D. Pickar, M. Linnoila, and W.Z. Potter Plasma norepinephrine level in affective disorders. Relationship to melancholia Archives of general psychiatry 42 1985 1181 1185 (Pubitemid 16191178)
25. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, G. Niederehe, M.E. Thase, P.W. Lavori, B.D. Lebowitz, P.J. McGrath, J.F. Rosenbaum, H.A. Sackeim, D.J. Kupfer, J. Luther, and M. Fava Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am. J. Psychiatry 163 2006 1905 1917 (Pubitemid 44807782)
26. R.P. Shank, J.F. Gardocki, C.R. Schneider, J.L. Vaught, P.E. Setler, B.E. Maryanoff, and D.F. McComsey Preclinical evaluation of McN-5707 as a potential antidepressant J. Pharmacol. Exp. Ther. 242 1987 74 84 (Pubitemid 17112262)
27. A.M. Shaw, M. Boules, Y. Zhang, K. Williams, J. Robinson, P.R. Carlier, and E. Richelson Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050 Eur. J. Pharmacol. 555 2007 30 36 (Pubitemid 46013855)
28. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor Eur. J. Pharmacol. 461 2003 99 104 (Pubitemid 36174028)
29. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 73 2003 3175 3179 (Pubitemid 37237572)
30. D. Spinks, and G. Spinks Serotonin reuptake inhibition: an update on current research strategies Curr. Med. Chem. 9 2002 799 810 (Pubitemid 34506386)
31. J. Sporn, S.N. Ghaemi, M.R. Sambur, M.A. Rankin, J. Recht, G.S. Sachs, J.F. Rosenbaum, and M. Fava Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review Ann. Clin. Psychiatry 12 2000 137 140
32. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology 85 1985 367 370 (Pubitemid 15123115)
33. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br. J. Psychiatry 178 2001 234 241 (Pubitemid 32183606)
34. D.R. Thomas, D.R. Nelson, and A.M. Johnson Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor Psychopharmacology 93 1987 193 200 (Pubitemid 18013056)
35. D.T. Wong, and F.P. Bymaster Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors Adv. Exp. Med. Biol. 363 1995 77 95
36. S. Zhang, F. Fernandez, S. Hazeldine, J. Deschamps, J. Zhen, M.E. Reith, and A.K. Dutta Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters J. Med. Chem. 49 2006 4239 4247 (Pubitemid 44036667)
37. S. Zhang, J. Zhen, M.E. Reith, and A.K. Dutta Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5- benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner J. Med. Chem. 48 2005 4962 4971 (Pubitemid 41038458)
38. J. Zhen, S. Maiti, N. Chen, A.K. Dutta, and M.E. Reith Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4- fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter Eur. J. Pharmacol. 506 2004 17 26 (Pubitemid 39575081)